ホーム › 非小細胞肺癌 › サウスカロライナ › Greenville
Greenville、SCにおける非小細胞肺癌の臨床試験
Greenvilleとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Saint Francis Cancer Center - Greenville /ID# 276368, Greenville
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Saint Francis Hospital, Greenville
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- 他2件
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
被験者募集中第3相
- Bon Secours Hematology and Oncology, Greenville
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Greenville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- St Francis Cancer Center, Greenville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- PRISMA Health/ITOR, Greenville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Greenville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Prisma Health Cancer Institute, Greenville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Greenville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Greenville Memorial Hospital, Greenville
- 他1件
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Saint Francis Hospital, Greenville
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- 他2件
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Greenville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 108, Greenville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Greenville
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Greenvilleにおける他の研究
- 乳がん12件の研究
- 急性骨髄性白血病10件の研究
- がん（全種類）9件の研究
- 肥満症9件の研究
- 肺がん9件の研究
- 過体重8件の研究
- 前立腺がん7件の研究
- 大腸癌7件の研究
- 胃癌6件の研究
- 末梢動脈疾患5件の研究
- バーキットリンパ腫5件の研究
- 悪性黒色腫5件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。